ARCHIVES

Children With Recurrent Hodgkin’s Respond To Gemcitabine, Vinorelbine

This article is from The Cancer Letter archive.

Vol. 32 No. 3 | March 27, 2009

Download PDF Visit The Full Archive

Related Articles

Tamoxifen: No Mortality Benefit For Most “High Risk” Women

September 29, 2006

Cancer Policy; Board Suggests More Detailed Items In Tobacco Agreement

August 22, 1997

Drug Development: Tivozanib Trial Discontinued Due to Insufficient Enrollment

February 7, 2014

Foundations: Biomedical Foundation Formed to Support NIH

September 27, 1996

NCCS Networker Volume 8 Issue 3, Fall 1994

September 12, 1994

Blumenthal Names Presidential Advisor; Groups Lobby To Limit Her Influence

October 3, 1997